MCL1 and primary cutaneous T-cell non-Hodgkin lymphoma: For evaluation of the possible therapeutic potential of selective Mcl-1 inhibitors in CTCL, four representative cell lines (HH, HuT-78, MyLa and SeAx) were treated with increasing concentrations of S63845 (0.25, 0.5, 1.0 μM).